Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT07050160
Enrolling by invitation Observational

Long-term Follow-up Study of Gene Therapy for Arrhythmogenic Cardiomyopathy Due to a Plakophilin-2 Pathogenic Variant

NCT07050160 · tracked via the Priya Life Science USA tracker
Sponsor
Lexeo Therapeutics
Phase
Observational
Started
2025-08-29
Last updated
2025-11-12

Condition(s) studied

Arrhythmogenic CardiomyopathyPKP2-ACMPKP2-ARVC

Study summary

The primary objective of this Phase 1/2 long-term follow-up (LTFU) study is to assess the long-term safety and tolerability of LX2020 for the treatment of arrhythmogenic cardiomyopathy (ACM) due to a plakophilin-2 gene (PKP2) pathogenic variant (PKP2-ACM).

Eligibility

Sex
ALL
Min age
18 Years
Max age
67 Years
Healthy volunteers
No
Inclusion Criteria: * Participants who received LX2020 in study LX2020-01 Exclusion Criteria: * Concurrent enrollment in any other clinical investigation involving use of an investigational agent.

Primary outcome measure(s)

  • Percentage of subjects who experienced at least 1 treatment emergent adverse event (TEAE) and/or 1 treatment emergent serious adverse event (TESAE). — 4 years
    Evaluation of Safety and Tolerability of LX2020

Trial sites (1)

FacilityCityRegionStatus
University of Michigan Ann Arbor Michigan

More Lexeo Therapeutics trials in the USA

A Study to Assess Real-world Patient Characteristics and Clinical Course for Symptomatic Patients With PKP2-ACM Recruiting
Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia Active, not recruiting
Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy Recruiting
Clinical Course Of Disease In Participants With FA-CM Recruiting
Long-Term Follow-up of Gene Therapy for APOE4 Homozygote Alzheimer's Disease Active, not recruiting

Other trials for the same condition

A Study to Assess Real-world Patient Characteristics and Clinical Course for Symptomatic Patients With PKP2-ACM Recruiting
Gene Therapy for ACM Due to a PKP2 Pathogenic Variant Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07050160 on ClinicalTrials.gov ↗ ← All trials in the USA